Guardant Health positions itself at the center of precision oncology and says its work uses biomarkers and circulating tumor DNA to guide personalized cancer care, as reported by Guardant Health.
The company describes precision oncology as a data driven approach that moves beyond traditional standards of care to inform treatment for advanced cancer and to monitor disease across stages, according to Guardant Health.
Guardant Health says circulating tumor DNA can assess response to treatment and detect signs of remaining cancer, and it can help identify the earliest signs of cancer, as reported by Guardant Health.
Founded in 2012, the company says it transforms patient care through advanced blood and tissue tests, real world data and AI analytics, as described by Guardant Health.
Impact And Operations
Guardant Health reports its tests support screening to find cancer early, monitoring for recurrence in early stage cancer, and treatment selection for patients with advanced cancer, as stated by the company.
The company describes its mission as guarding wellness and giving every person more time free from cancer, and it lists a primary address at 3100 Hanover Street Palo Alto California 94304, as reported by Guardant Health.
Guardant Health also lists additional locations including 505 Penobscot Dr Redwood City California 94063, 720 3rd Ave Suite 2100 Seattle Washington 98104, and offices in Spring Texas San Diego Singapore Shanghai India Tokyo and New York, as reported by the company.
The company issues an important note for job applicants warning of recruiting scams and states it will never ask for money or credit card information during applications, nor will it communicate via online chatrooms or personal email accounts such as Gmail or Hotmail, as reported by Guardant Health.
